Bevacizumab in newly diagnosed ovarian cancer
Mené sur 1 528 patientes atteintes d'un cancer de l'ovaire récemment diagnostiqué, cet essai randomisé international évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du bévacizumab à une chimiothérapie de référence
Several studies have assessed the activity of bevacizumab when added to chemotherapy in ovarian cancer. In Europe, bevacizumab is approved by the European Medicines Agency in combination with carboplatin and paclitaxel in newly diagnosed ovarian cancer, with carboplatin and gemcitabine in platinum-sensitive relapse ovarian cancer, and with chemotherapy in platinum-resistant relapse ovarian cancer. In the USA, bevacizumab is approved by the Food and Drug Administration when combined with chemotherapy for platinum-resistant relapse ovarian cancer.
The Lancet Oncology , commentaire, 2014